Margin of Safety Dashboard

Kiniksa Pharmaceuticals

KNSA

$
44.90
(
-0.9
%)
(
+
-0.9
%)
+
-28.8
%
31.95
NASDAQ

Last Price

04/17/26, 09:30 AM
 EDT

Margin of Safety

Current Compounder
$
31.95

PORTFOLIO CATEGORY

Modeled fair value

Up to 10%
$2.422 billion

Allocation Suggestion

Modeled fair value

Model Basis

LAST REFINED:
November 2, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Component A: Arcalyst commercial ramp in recurrent pericarditis. Full-year 2025 revenue of $681.321 million
  • Component B: Risk-weighted contributions from KPL-387 in recurrent pericarditis
The current model EXCLUDES the following assets:
  • KPL-1161 in recurrent pericarditis (preclinical)

SEC Filings

Show More
Back to Top
ABOUT
What Is Solt DB?
Public Benefit
Our Lonely Team
PUBLIC CONTENT
Articles
Data Visualizations
Newsletter
INVESTING
Pricing
Member Benefits
Stocks We Cover
CONTACT
Questions?
Critiques?
Love letters?

Reach out here.
About Solt DB

Solt DB is an equities research firm and public benefit company exploring the business of biotech. For scientists, investors, and nerds of all stripes – or feathers.

Yinz respect the finch n@. 2026 Solt DB.
A white logo of LinkedIn.